Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Lilly was the first company to cap insulin prices at $35

  80% confidence

• Today marks a pivotal moment in U.S. health care policy and a defining milestone for Lilly, made possible through collaboration with the Trump Administration

  80% confidence

• This agreement expands access to obesity treatments for more Americans while advancing one of the most innovative obesity pipelines

  80% confidence

• Agreement will improve access to nearly 40 million Americans living with obesity on government insurance programs and millions more who pay out-of-pocket

  80% confidence

• Lilly is investing more than $50 billion in U.S. manufacturing to boost domestic production in key therapeutic areas

  80% confidence

• Obesity is a risk factor driving more than 200 associated diseases, including heart disease, strokes and certain types of cancers

  80% confidence

• The U.S. health care system has evolved in a way that's unfair to American patients and taxpayers who disproportionately pay a higher share of the costs for developing breakthrough medicines compared to other countries

  80% confidence

• Lilly is in a unique position to work with the U.S. government to rebalance the global system, expand access and lower costs for Americans while protecting ability to innovate and enhance manufacturing capacity

  80% confidence